Anima opens new target space in translational control
How Anima is leveraging its translational control platform to pursue new targets, small molecules and big pharma deals
Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg up over competitors looking to bind RNA directly, in terms of target stability, tissue selectivity and the ability to tune protein expression up or down.
Anima Biotech Inc. was launched in 2014 with technology from the University of Pennsylvania that lets it visualize translation of almost any protein, enabling it to track how different molecules impact the process. ...